Epigenetics of hepatocellular carcinoma: a new horizon

( views:475, downloads:0 )
Author:
LIU Wei-ren(Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032,China)
SHI Ying-hong(Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032,China;Institute of Biomedical Sciences, Fudan University, Shanghai 200032. China)
PENG Yuan-fei(Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032,China)
FAN Jia(Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032,China;Institute of Biomedical Sciences, Fudan University, Shanghai 200032. China)
Journal Title:
Chinese Medical Journal
Issue:
Volume 125, Issue 13, 2012
DOI:
10.3760/cma.j.issn.0366-6999.2012.13.020
Key Word:
hepatocellular carcinoma;epigenetic;DNA methylation;miRNA

Abstract: Epigenetic changes refer to stable alterations in gene expression with no underlying modifications in the genetic sequence itself.It has become clear that not only gene variations but also epigenetic modifications may contribute to varied diseases,including cancer.This review will provide an overview of how epigenetic factors,including genomic DNA methylation,histone modifications,and miRNA regulation,contribute to hepatocellular carcinoma (HCC) dissemination,invasion,and metastasis.Additionally,the reversal of dysregulated epigenetic changes has emerged as a potential strategy for the treatment of HCC,and we will summarize the latest epigenetic therapies for HCC.

  • 1.Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin 2011; 61:69-90.
  • 2.Siegel R,Ward E,Brawley O,Jemal A.Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin 2011; 61:212-236.
  • 3.Dumitrescu RG.Epigenetic targets in cancer epidemiology.Methods Mol Biol 2009; 471:457-467.
  • 4.Piperi C,Vlastos F,Farmaki E,Martinet N,Papavassiliou AG.Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis.J Cell Mol Med 2008; 12:1495-1501.
  • 5.Jones PA,Baylin SB.The epigenomics of cancer.Cell 2007;128:683-692.
  • 6.Jovanovic J,Ronneberg JA,Tost J,Kristensen V.The epigenetics of breast cancer.Mol Oncol 2010; 4:242-254.
  • 7.Zang JJ,Xie F,Xu JF,Qin YY,Shen RX,Yang JM,et al.P16 gene hypermethylation and hepatocellular carcinoma:a systematic review and meta-analysis.World J Gastroenterol 2011; 17:3043-3048.
  • 8.Oleinik NV,Krupenko NI,Krupenko SA.Epigenetic silencing of ALDH1L1,a metabolic regulator of cellular proliferation,in Cancers.Genes Cancer 2011; 2:130-139.
  • 9.Chen M,Zhang J,Li N,Qian Z,Zhu M,Li Q,et al.Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer.PLoS One 2011; 6:e25564.
  • 10.Braconi C,Kogure T,Valeri N,Huang N,Nuovo G,Costinean S,et al.microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.Oncogene 2011; 30:4750-4756.
  • 11.Acun T,Oztas E,Yagci T,Yakicier MC.SIPI is dowuregulated in hepatocellular carcinoma by promoter hypermethylation.BMC Cancer 2011; 11:223.
  • 12.Sceusi EL,Loose DS,Wray CJ.Clinical implications of DNA methylatinn in hepatocellular carcinoma.HPB (Oxford)2011; 13:369-376.
  • 13.Herceg Z, Paliwal A.Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.Mutat Res 2011; 727:55-61.
  • 14.Cheung HH,Davis A J,Lee TL,Pang AL,Nagrani S,Rennert OM,et al.Methylation of an intronic region regulates miR-199a in testicular tumor malignancy.Oncogene 2011;30:3404-3415.
  • 15.Bird A.DNA methylation patterns and epigenetic memory.Genes Dev 2002; 16:6-21.
  • 16.Vanyushin BF,Tkacheva SG,Belozersky AN.Rare bases in animal DNA.Nature 1970; 225:948-949.
  • 17.Egger G,Liang G,Aparicio A,Jones PA.Epigenetics in human disease and prospects for epigenetic therapy.Nature 2004; 429:457-463.
  • 18.Klose RJ,Bird AP.Genomic DNA methylation:the mark and its mediators.Trends Biochem Sci 2006; 31:89-97.
  • 19.Lopez-Serra L,Esteller M.Proteins that bind methylated DNA and human cancer:reading the wrong words.Br J Cancer 2008; 98:1881-1885.
  • 20.Esteller M.Epigenetic gene silencing in cancer:the DNA hypermethylome.Hum Mol Genet 2007; 16:R50-R59.
  • 21.Kuroda A,Rauch TA,Todorov I,Ku HT,Al-Abdullah IH,Kandeel F,et al.Insulin gene expression is regulated by DNA methylation.PLoS One 2009; 4:e6953.
  • 22.Jurkowska RZ,Jeltsch A.Silencing of gene expression by targeted DNA methylation: concepts and approaches.Methods Mol Biol 2010; 649:149-161.
  • 23.Kim JK, Samaranayake M, Pradhan S.Epigenetic mechanisms in mammals.Cell Mol Life Sci 2009; 66:596-612.
  • 24.You H,Ding W,Rountree CB.Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta.Hepatology 2010; 51:1635-1644.
  • 25.Chun JY,Bae JS,Park TJ,Kim JY,Park BL,Cheong HS,et al.Putative association of DNA methyltransferase 1 (DNMT1) polymorphisms with clearance of HBV infection.BMB Rep 2009; 42:834-839.
  • 26.Datta J,Ghoshal K,Denny WA,Gamage SA,Brooke DG,Phiasivongsa P,et al.A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.Cancer Res 2009; 69:4277-4285.
  • 27.Saito Y,Kanai Y,Nakagawa T,Sakamoto M,Saito H,Ishii H,et al.Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas.Int J Cancer 2003; 105:527-532.
  • 28.Lin CH,Hsieh SY,Sheen IS,Lee WC,Chen TC,Shyu WC,et al.Genome-wide hypomethylation in hepatocellular carcinogenesis.Cancer Res 2001; 61:4238-4243.
  • 29.Hoofnagle JH,Doo E,Liang T J,Fleischer R,Lok AS.Management of hepatitis B:summary of a clinical research workshop.Hepatology 2007; 45:1056-1075.
  • 30.Lok AS,Heathcote E J,Hoofragle JH.Management of hcpatitis B: 2000 -- summary of a workshop.Gastroenterology 2001; 120:1828-1853.
  • 31.Zhu R,Zhang JS,Zhu YZ,Fan J,Mao Y,Chen Q,et al.HBx-induced androgen receptor expression in HBV-associated hepatocarcinoma is independent of the methylation status of its promoter.Histol Histopathol 2011;26:23-35.
  • 32.Zheng DL,Zhang L,Cheng N,Xu X,Deng Q,Teng XM,et al.Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A.J Hepatol 2009; 50:377-387.
  • 33.Park IY,Sohn BH,Yu E,Suh DJ,Chung YH,Lee JH,et al.Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.Gastroenterology 2007; 132:1476-1494.
  • 34.Gibney ER,Nolan CM.Epigenetics and gene expression.Heredity (Edinb) 2010; 105:4-13.
  • 35.Razin A.CpG methylation,chromatin structure and gene silencing-a three-way connection.EMBO J 1998; 17:4905-4908.
  • 36.Chatagnon A,Bougel S,Perriand L,Lachuer J,Benhattar J,Dante R.Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells.Carcinogenesis 2009;30:28-34.
  • 37.Ghoshal K,Li X,Datta J,Bai S,Pogribny I,Pogribny M,et al.A folate-and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats.J Nutr 2006; 136:1522-1527.
  • 38.Howell PM Jr,Liu S,Ren S,Behlen C,Fodstad O,Riker AI.Epigenetics in human melanoma.Cancer Control 2009; 16:200-218.
  • 39.Jain S,Chang TT,Hamilton JP,Lin SY,Lin YJ,Evans AA,et al.Methylation of the CpG Sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma.PLoS One 2011; 6:e26799.
  • 40.Huang J,Lin Y,Li L,Qing D,Teng XM,Zhang YL,et al.ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma,could contribute to hepatocarcinogenesis.Mol Carcinog 2009; 48:130-140.
  • 41.Ko E,Kim Y,Kim SJ,Joh JW,Song S,Park CK,et al.Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.Cancer Epidemiol Biomarkers Prey 2008; 17:2260-2267.
  • 42.Csepregi A,Ebert MP,Rocken C,Schneider-Stock R,Hoffmann J,Schulz HU,et al.Promoter mcthylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.BMC Cancer 2010; 10:317.
  • 43.Qiu GH,Salto-Tellez M,Ross JA,Yeo W,Cui Y,Wheelhouse N,et al.The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.J Hepatol 2008; 48:433-441.
  • 44.Nomoto S,Kanda M,Okamara Y,Nishikawa Y,Qiyong L,Fujii T,et al.Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.Ann Surg Oncol 2010; 17:923-932.
  • 45.Kanda M,Nomoto S,Okamura Y,Hayashi M,Hishida M,Fnjii T,et al.Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma.Mol Carcinog 2011; 50:571-579.
  • 46.Tada M,Kanai F,Tanaka Y,Tateishi K,Ohta M,Asaoka Y,et al.Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma.Clin Cancer Res 2008; 14:3768-3776.
  • 47.Zhang Y J,Li H,Wu HC,Shen J,Wang L,Yu MW,et al.Silencing of Hint1,a novel tumor suppressor gene,by promoter hypermethylation in hepatocellular carcinoma.Cancer Lett 2009; 275:277-284.
  • 48.Lu CY,Hsieh SY,Lu Y J,Wu CS,Chen LC,Lo SJ,et al.Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.Genes Chromosomes Cancer 2009; 48:1057-1068.
  • 49.Okamura Y,Nomoto S,Kanda M,Li Q,Nishikawa Y,Sugimoto H,et al.Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array.Cancer Lett 2010; 289:170-177.
  • 50.Kanda M,Nomoto S,Okamura Y,Nishikawa Y,Sugimoto H,Kanazumi N,et al.Detection of metallothionein IG as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis.Int J Oncol 2009; 35:477-483.
  • 51.Fukui M.Altered glomerular mRNA expression of basement membrane components and type Ⅰ collagen in diabetic rats treated with or without insulin therapy.Nihon Jinzo Gakkai Shi 1991; 33:275-281.
  • 52.Saelee P,Wongkham S,Chariyalertsak S,Petmitr S,Chuensumran U.RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.Asian Pac J Cancer Prev 2010; 11:1677-1681.
  • 53.Nomoto S,Kinoshita T,Kato K,Otani S,Kasuya H,Takeda S,et al.Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma.Br J Cancer 2007; 97:1260-1265.
  • 54.Huang J,Zheng DL,Qin FS,Cheng N,Chen H,Wan BB,et al.Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.J Clin Invest 2010; 120:223-241.
  • 55.Um TH,Kim H,Oh BK,Kim MS,Kim KS,Jung G,et al.Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.J Hepatol 2011; 54:939-947.
  • 56.Fu L,Dong SS,Xie YW,Tai LS,Chen L,Kong KL,et al.Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma.Hepatology 2010; 51:1624-1634.
  • 57.Lu B,Ma Y,Wu G,Tong X,Guo H,Liang A,et al.Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.Clin Cancer Res 2008; 14:7405-7412.
  • 58.Huang L,Li MX,Wang L,Li BK,Chen GH,He LR,et al.Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation.Tumour Biol 2011; 32:233-240.
  • 59.Soares J,Pinto AE,Cunha CV,Andre S,Barao I,Sousa JM,et al.Global DNA hypomethylation in breast carcinoma:correlation with prognostic factors and tumor progression.Cancer 1999; 85:112-118.
  • 60.Bernardino J,Ronx C,Almeida A,Vogt N,Gibaud A,Gerbault-Seureau M,et al.DNA hypomethylation in breast cancer:an independent parameter of tumor progression?Cancer Genet Cytogenet 1997; 97:83-89.
  • 61.Baylin SB,Herman JG,Graft JR,Vertino PM,Issa JP.Alterations in DNA methylation:a fundamental aspect of neoplasia.Adv Cancer Res 1998; 72:141-196.
  • 62.Berdasco M,Esteller M.Aberrant epigenetic landscape in cancer:how cellular identity goes awry.Dev Cell 2010; 19:698-711.
  • 63.Son KS,Kang HS,Kim S J,Jung SY,Min SY,Lee SY,et al.Hypomethylation of the interleukin-10 gene in breast cancer tissues.Breast 2010; 19:484-488.
  • 64.Kitamoto S,Yamada N,Yokoyama S,Houjou I,Higashi M,Yonezawa S.Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.Biochem Biophys Res Commun 2010; 397:333-339.
  • 65.Reed K,Hembruff SL,Sprowl JA,Parissenti AM.The temporal relationship between ABCB1 promoter hypomethylation,ABCB1 expression and acquisition of drug resistance.Pharmacogenomics J 2010; 10:489-504.
  • 66.Sharma G,Mirza S,Parshad R,Srivastava A,Datta Gupta S,Pandya P,et al.CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients.Clin Biochem 2010; 43:373-379.
  • 67.Quante M,Tu SP,Tomita H,Gonda T,Wang SS,Takashi S,et al.Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.Cancer Cell 2011; 19:257-272.
  • 68.Dong W,Wang L,Chen X,Sun P,Wu Y.Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer.Dig Dis Sci 2010; 55:997-1003.
  • 69.Lim JH,Kim SP,Gabrielson E,Park YB,Park JW,Kwon TK.Activation of human cancer/testis antigen gene,XAGE-1,in tumor cells is correlated with CpG island hypomethylation.Int J Cancer 2005; 116:200-206.
  • 70.Nishigaki M,Aoyagi K,Danjoh I,Fukaya M,Yanagihara K,Sakamoto H,et al.Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays.Cancer Res 2005; 65:2115-2124.
  • 71.Cho M,Uemura H,Kim SC,Kawada Y,Yoshida K,Hirao Y,et al.Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma.Br J Cancer 2001; 85:563-567.
  • 72.Iramaneerat K, Rattanatunyong P, Khemapech N,Triratanachat S,Mutirangura A.HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.lnt J Gynecol Cancer 2011; 21:51-57.
  • 73.Cheng W,Jiang Y,Liu C,Shen O,Tang W,Wang X.Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer.J Cancer Res Clin Oncol 2010;136:1221-1227.
  • 74.Wolff EM,Byun HM,Han HF,Shanna S,Nichols PW,Siegmund KD,et al.Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer.PLoS Genet 2010; 6:e1000917.
  • 75.Del Senno L,Maestri I,Piva R,Hanau S,Reggiani A,Romano A,et al.Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades.J Urol 1989; 142:146-149.
  • 76.Vestergaard EM,Nexo E,Torring N,Bone M,Orntoft TF,Sorensen KD.Promoter hypomethylation and upregulation of trefoil factors in prostate cancer.Int J Cancer 2010; 127:1857-1865.
  • 77.Karpf AR,Bai S,James SR,Mohler JL,Wilson EM.Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.Mol Cancer Res 2009; 7:523-535.
  • 78.Ramzy,Ⅱ,Omran DA,Hamad O,Shaker O,Abboud A.Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma.Arab J Gastroenterol 2011; 12:139-142.
  • 79.Kong LM,Liao CG,Chen L,Yang HS,Zhang SH,Zhang Z,et al.Promoter hypomethylation up-regulates CD147 expression through increasing Spl binding and associates with poor prognosis in human hepatocellular carcinoma.J Cell Mol Med 2011; 15:1415-1428.
  • 80.Xiao J,Chen HtS,Fei R,Cong X,Wang LP,Wang Y,et al.Expression of MAGE-A1 mRNA is associated with gene hypomethylation in hepatocarcinoma cell lines.J Gastroenterol 2005; 40:716-721.
  • 81.Okada H,Kimura MT,Tan D,Fujiwara K,Igarashi J,Makuuchi M,et al.Frequent trefoil factor 3 (TFF3)overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas.Int J Oncol 2005; 26:369-377.
  • 82.Peng SY,Lai PL,Chu JS,Lee PH,Tsung PT,Chen DS,et al.Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas.Hepatology 1993; 17:35-41.
  • 83.Youngblood B,Oestreich KJ,Ha S J,Duraiswamy J,Akondy RS,West EE,et al.Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.Immunity 2011; 35:400-412.
  • 84.Lan VV,Grady WM.Epigenetics and colorectal cancer.Nat Rev Gastroenterol Hepatol 2011; 8:686-700.
  • 85.Firlej V,Mathieu JR,Gilbert C,Lemonnier L,Nakhle J,Gallou-Kabani C,et al.Thrombospondin-1 triggers cell migration and development of advanced prostate tumors.Cancer Res 2011; 71:7649-7658.
  • 86.Dango S,Mosammaparast N,Sowa ME,Xiong L J,Wu F,Park K,et al.DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation.Mol Cell 2011; 44:373-384.
  • 87.Chatagnon A,Perriaud L,Nazaret N,Croze S,Berthattar J,Lachuer J,et al.Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions.Epigenetics 2011; 6[Epub ahead of print].
  • 88.Andersen JB,Factor VM,Marquardt JU,Raggi C,Lee YH,Seo D,et al.An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.Sci Transl Med 2010; 2:54ra77.
  • 89.Jiang C,Zhou B,Fan K,Henng E,Xue L,Liu X,et al.A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells.Anticancer Res 2007; 27:3783-3789.
  • 90.Kanda T,Tada M,Imazeki F,Yokosuka O,Nagao K,Saisho H.5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.Oncol Rep 2005; 14:975-979.
  • 91.Murata H,Tsuji S,Tsujii M,Sakaguchi Y,Fu HY,Kawano S,et al.Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.Lab Invest 2004; 84:1050-1059.
  • 92.van Malenstein H,van Pelt J,Verslype C.Molecular classification of hepatocellular carcinoma anno 2011.Eur JCancer 2011; 47:1789-1797.
  • 93.Sugita H,Iida S,Inokuchi M,Kato K,Ishiguro M,Ishikawa T,et al.Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer.Oncol Rep 2011; 25:513-518.
  • 94.lizuka N,Oka M,Sakaida I,Moribe T,Miura T,Kimura N,et al.Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers.Clin Chim Acta 2011; 412:152-158.
  • 95.Collignon J,Struman I,Tabruyn S,Josse C,Boukerroucha M,Jerusalem G,et al.Molecular and genetic aspects of triple negative breast cancer and therapeutic implications.Rev Med Liege 2011; 66:393-396.
  • 96.Zeller C,Brown R.Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.Ther Adv Med Oncol 2010; 2:319-329.
  • 97.Zhu J.DNA methylation and hepatocellular carcinoma.J Hepatobiliary Pancreat Surg 2006; 13:265-273.
  • 98.Yuan Y,Wang J,Li J,Wang L,Li M,Yang Z,et al.Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.Clin Cancer Res 2006; 12:6687-6695.
  • 99.Kitamura Y,Shirahata A,Sakuraba K,Goto T,Mizukami H,Saito M,et al.Aberrant methylation of the Vimentin gene in hepatocellular carcinoma.Anticancer Res 2011; 31:1289-1291.
  • 100.Okamura Y,Nomoto S,Kanda M,Hayashi M,Nishikawa Y,Fujii T,et al.Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma.Ann Surg Oncol 2011; 18:572-579.
  • 101.Moribe T,Iizuka N,Miura T,Kimura N,Tamatsukuri S,Ishitsuka H,et al.Methylation of multiple genes as molecular markers for diagnosis of a small,well-differentiated hepatocellular carcinoma.Int J Cancer 2009; 125:388-397.
  • 102.Moribe T,Iizuka N,Miura T,Stark M,Tamatsukuri S,Ishitsuka H,et al.Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.Int J Oncol 2008; 33:949-958.
  • 103.Zhang Y J,Wu HC,Shen J,Ahsan H,Tsai WY,Yang HI,et al.Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.Clin Cancer Res 2007;13:2378-2384.
  • 104.Berger SL,Kouzarides T,Shiekhattar R,Shilatifard A.An operational definition of epigenetics.Genes Dev 2009; 23:781-783.
  • 105.Yang XJ.The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.Nucleic Acids Res 2004; 32:959-976.
  • 106.Smith EM,Boyd K,Davies FE.The potential role of epigenetic therapy in multiple myeloma.Br J Haematol 2010;148:702-713.
  • 107.Lei W,Zhang K,Pan X,Hu Y,Wang D,Yuan X,et al.Histone deacetylase 1 is required for transforming growth factor-betal-induced epithelial-mesenchymal transition.Int J Biochem Cell Biol 2010; 42:1489-1497.
  • 108.Quint K,Agaimy A,Di Fazio P,Montalbano R,Steindorf C,Jung R,et al.Clinical significance of histone deacetylases 1,2,3,and 7:HDAC2 is an independent predictor of survival in HCC.Virchows Arch 2011; 459:129-139.
  • 109.Cheng AS,Lau SS,Chen Y,Kondo Y,Li MS,Feng H,et al.EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis.Cancer Res 2011; 71:4028-4039.
  • 110.Bhaskara S,Knutson SK,Jiang G,Chandrasekharan MB,Wilson AJ,Zheng S,et al.Hdac3 is essential for the maintenance of chromatin structure and genome stability.Cancer Cell 2010; 18:436-447.
  • 111.Choi HN,Bae JS,Jamiyandorj U,Noh S J,Park HS,Jang KY,et al.Expression and role of SIRT1 in hepatocellular carcinoma.Oncol Rep 2011; 26:503-510.
  • 112.Chen J,Zhang B,Wong N,Lo AW,To KF,Chan AW,et al.Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.Cancer Res 2011; 71:4138-4149.
  • 113.Cleary J,Sitwala KV, Khodadoust MS,Kwok RP,Mor-Vaknin N,Cebrat M,et al.p300/CBP-associated factor drives DEK into interchromatin granule clusters.J Biol Chem 2005; 280:31760-31767.
  • 114.Martin C,Zhang Y.The diverse functions of histone lysine methylation.Nat Rev Mol Cell Biol 2005; 6:838-849.
  • 115.Zhang Y,Reinberg D.Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails.Genes Dev 2001; 15:2343-2360.
  • 116.Spannhoff A,Hanser AT,Heinke R,Sippl W,Jung M.The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.ChemMedChem 2009; 4:1568-1582.
  • 117.Hublitz P, Albert M, Peters AH.Mechanisms of transcriptional repression by histone lysine methylation.Int J Dev Biol 2009; 53:335-354.
  • 118.Barski A,Cuddapah S,Cui K,Roh TY,Schones DE,Wang Z,et al.High-resolution profiling of histone methylations in the human genome.Cell 2007; 129:823-837.
  • 119.Whetstine JR,Nottke A,Lan F,Huarte M,Smolikov S,Chen Z,et al.Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.Cell 2006; 125:467-481.
  • 120.Tsukada Y,Fang J,Erdjument-Bromage H,Warren ME,Borchers CH,Tempst P,et al.Histone demethylation by a family of JmjC domain-containing proteins.Nature 2006;439:811-816.
  • 121.Yang L,He J,Chen L,Wang G.Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.Med Oncol 2009; 26:445-451.
  • 122.Tsuge M,Hamamoto R,Silva FP,Ohnishi Y,Chayama K,Kamatani N,et al.A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.Nat Genet 2005; 37:1104-1107.
  • 123.Hamamoto R,Furukawa Y,Morita M,Iimura Y,Silva FP,Li M,et al.SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.Nat Cell Biol 2004; 6:731-740.
  • 124.Fang W,Piao Z,Simon D,Sheu JC,Huang S.Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2)gene localized to the region.Genes Chromosomes Cancer 2000; 28:269-275.
  • 125.Magerl C,Ellinger J,Braunschweig T,Kremmer E,Koch LK,Holler T,et al.H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.Hum Pathol 2010;41:181-189.
  • 126.Osawa T,Muramatsu M,Wang F,Tsuchida R,Kodama T,Minami T,et al.Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.Proc Natl Acad Sci U S A 2011; 108:20725-20729.
  • 127.Taby R,Issa JP.Cancer epigenetics.CA Cancer J Clin 2010;60:376-392.
  • 128.Mann BS,Johnson JR,Cohen MH,Justice R,Pazdur R.FDA approval summary:vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.Oncologist 2007; 12:1247-1252.
  • 129.Carew JS,Giles FJ,Nawrocki ST.Histone deacetylase inhibitors:mechanisms of cell death and promise in combination cancer therapy.Cancer Lett 2008; 269:7-17.
  • 130.Carlisi D,Vassallo B,Lauricella M,Emanuele S,D'Atneo A,Di Leonardo E,et al.Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.Int J Oncol 2008; 32:177-184.
  • 131.Chen MC,Chen CH,Chuang HC,Kulp SK,Teng CM,Chen CS.Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells.Hepatology 2011; 53:148-159.
  • 132.Liu YL,Yang PM,Shun CT,Wu MS,Weng JR,Chen CC.Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.Autophagy 2010; 6:1057-1065.
  • 133.Gahr S,Peter G,Wissniowski TT,Hahn EG,Herold C,Ocker M.The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.Oncol Rep 2008; 20:1249-1256.
  • 134.Machado MC,Bellodi-Privato M,Kubrusly MS,Molan NA,Tharcisio T Jr,de Oliveira ER,et al.Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.J Exp Ther Oncol 2011; 9:85-92.
  • 135.Zhang CZ,Zhang HT,Chen GG,Lai PB.Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment.Apoptosis 2011; 16:683-695.
  • 136.Yang H,Nie Y,Li Y,Wan YJ.Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells.Exp Biol Med (Maywood) 2010; 235:32-39.
  • 137.Ma BB,Sung F,Tao Q,Poon FF,Lui VW,Yeo W,et al.The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.Invest New Drugs 2010; 28:107-114.
  • 138.Greiner D,Bonaldi T,Eskeland R,Roemer E,Imhof A.Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.Nat Chem Biol 2005; 1:143-145.
  • 139.Tan J,Yang X,Zhuang L,Jiang X,Chen W,Lee PL,et al.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev 2007; 21:1050-1063.
  • 140.Chiba T,Suzuki E,Negishi M,Saraya A,Miyagi S,Konuma T,et al.3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.Int J Cancer 2012; 130:2557-2567.
  • 141.Carthew RW,Sontheimer EJ.Origins and mechanisms of miRNAs and siRNAs.Cell 2009; 136:642-655.
  • 142.Gregory RI,Chendrimada TP,Cooch N,Shiekhattar R.Human RISC couples microRNA biogenesis and posttranscriptional gene silencing.Cell 2005; 123:631-640.
  • 143.Brennecke J,Stark A,Russell RB,Cohen SM.Principles of microRNA-target recognition.PLoS Biol 2005; 3:e85.
  • 144.Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function.Cell 2004; 116:281-297.
  • 145.Carleton M,Cleary MA,Linsley PS.MicroRNAs and cell cycle regulation.Cell Cycle 2007; 6:2127-2132.
  • 146.Boehm M,Slack FJ.MicroRNA control of lifespan and metabolism.Cell Cycle 2006; 5:837-840.
  • 147.Harfe BD.MicroRNAs in vertebrate development.Curt Opin Genet Dev 2005; 15:410-415.
  • 148.Iorio MV,Piovan C,Croce CM.Interplay between microRNAs and the epigenetic machinery:an intricate network.Biochim Biophys Acta 2010; 1799:694-701.
  • 149.Calin GA,Sevignani C,Dumitru CD,Hyslop T,Noch E,Yendamuri S,et al.Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.Proc Natl Acad Sci U S A 2004; 101:2999-3004.
  • 150.Valeri N,Vannini I,Fanini F,Calore F,Adair B,Fabbri M.Epigenetics,miRNAs,and human cancer:a new chapter in human gene regulation.Mamm Genome 2009; 20:573-580.
  • 151.Kojima K,Takata A,Vadnais C,Otsuka M,Yoshikawa T,Akanuma M,et al.MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.Nat Commun 2011; 2:338.
  • 152.Fan CG,Wang CM,Tian C,Wang Y,Li L,Sun WS,et al.miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.Oncol Rep 2011; 26:1281-1286.
  • 153.Jung CJ,lyengar S,Blahnik KR,Ajuha TP,Jiang JX,Famham PJ,et al.Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation.PLoS One 2011; 6:e27740.
  • 154.Zheng F,Liao YJ,Cai MY,Liu YH,Liu TH,Chen SP,et al.The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.Gut 2012; 61:278-289.
  • 155.Liu S,Guo W,Shi J,Li N,Yu X,Xue J,et al.MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma.J Hepatol 2012; 56:389-396.
  • 156.Wu L,Cai C,Wang X,Liu M,Li X,Tang H.MicroRNA-142-3p,a new regulator of RAC1,suppresses the migration and invasion of hepatocellular carcinoma cells.FEBS Lett 2011 ; 585:1322-1330.
  • 157.Krutzfeldt J,Rosch N,Hausser J,Manoharan M,Zavolan M,Stoffel M.MicroRNA-194 is a target of transcription factor 1 (Tcfl,Hnflalpha) in adult liver and controls expression of frizzled-6.Hepatology 2012; 55:98-107.
  • 158.Tan S,Li R,Ding K,Lobie PE,Zhu T.miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.FEBS Lett 2011; 585:2229-2234.
  • 159.Jia XQ,Cheng HQ,Qian X,Bian CX,Shi ZM,Zhang JP,et al.Lentivirus-mediated overexpression of MicroRNA-199a inhibits cell proliferation of human hepatocellular carcinoma.Cell Biochem Biophys 2012; 62:237-244.
  • 160.Hou,Lin L,Zhou W,Wang Z,Ding G,Dong Q,et al.Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma.Cancer Cell 2011; 19:232-243.
  • 161.Shatseva T,Lee DY,Deng Z,Yang BB.MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.J Cell Sci 2011; 124:2826-2836.
  • 162.Wang C,Song B,Song W,Liu J,Sun A,Wu D,et al.Underexpressed microRNA-199b-Sp targets hypoxia-inducible factor-lalpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.J Gastroenterol Hepatol 2011; 26:1630-1637.
  • 163.Yuan JH,Yang F,Chen BF,Lu Z,Huo XS,Zhou WP,et al.The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.Hepatology 2011; 54:2025-2035.
  • 164.Vaira V,Faversani A,Dohi T,Montorsi M,Augello C,Gatti S,et al.miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression.Oncogene 2012; 31:27-38.
  • 165.Wang CM,Wang Y,Fan CG,Xu FF,Sun WS,Liu YG,et al.miR-29c targets TNFAIP3,inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.Biochem Biophys Res Commun 2011; 411:586-592.
  • 166.Huang XH,Chen JS,Wang Q,Chen XL,Wen L,Chen LZ,et al.miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened.J Pathol 2011; 225:463-472.
  • 167.Guo Y,Li S,Qu J,Wang S,Dang Y,Fan J,et al.MiR-34a inhibits lymphatic metastasis potential of mouse hepatoma cells.Mol Cell Biochem 2011; 354:275-282.
  • 168.Wu N,Liu X,Xu X,Fan X,Liu M,Li X,et al.MicroRNA-373,a new regulator of protein phosphatase 6,functions as an oncogene in hepatocellular carcinoma.FEBS J 2011; 278:2044-2054.
  • 169.He XX,Chang Y,Meng FY,Wang MY,Xie QH,Tang F,et al.MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.Oncogene 2011; doi:10.1038/onc.2011.500.[Epub ahead of print]
  • 170.Lin J,Huang S,Wu S,Ding J,Zhao Y,Liang L,et al.MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Vafl in hepatocellular carcinoma.Carcinogenesis 2011; 32:1641-1647.
  • 171.Guo Z,Wu C,Wang X,Wang C,Zhang R,Shan B.A polymorphism at the miR-502 binding site in the 3' untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome.lnt J Cancer 2011; doi:10.1002/ijc.27352.[Epub ahead of print]
  • 172.Zhou J,Wang W.Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell.J Surg Oncol 2011; 104:278-283.
  • 173.Toffanin S,Hoshida Y,Lachenmayer A,Villanueva A,Cabellos L,Minguez B,et al.MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.Gastroenterology 2011; 140:1618-1628el6.
  • 174.Hou YY,Can WW,Li L,Li SP,Liu T,Wan HY,et al.MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703.Cancer Lett 2011; 307:182-190.
  • 175.Zhang S,Shan C,Kong G,Du Y,Ye L,Zhang X.MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK).Oncogene 2011 doi:10.1038/onc.2011.523.[Epub ahead of Print].
  • 176.Zhang JF,He ML,Fu WM,Wang H,Chen LZ,Zhu X,et al.Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling.Hepatology 2011; 54:2137-2148.
  • 177.Li D,Liu X,Lin L,Hou J,Li N,Wang C,et al.MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma.J Biol Chem 2011; 286:36677-36685.
  • 178.Hu Z,Chen X,Zhao Y,Tian T,Jin G,Shu Y,et al.Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.J Clin Oncol 2010; 28:1721-1726.
  • 179.Chen X,Ba Y,Ma L,Cai X,Yin Y,Wang K,et al.Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases.Cell Res 2008; 18:997-1006.
  • 180.Wong CM,Wong CC,Lee JM,Fan DN,Au SL,Ng IO.Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis.Hepatology 2012; 55:1453-1461.
  • 181.Zhou J,Yu L,Gao X,Hu J,Wang J,Dai Z,et al.Plasma miuroRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.J Clin Oncol 2011; 29:4781-4788.
  • 182.Ji J,Shi J,Budhu A,Yu Z,Forgues M,Roessler S,et al.MicroRNA expression,survival,and response to interferon in liver cancer.N Engl J Med 2009; 361:1437-1447.
  • 183.Li LM,Hu ZB,Zhou ZX,Chen X,Liu FY,Zhang JF,et al.Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma.Cancer Res 2010; 70:9798-9807.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn